Dr. G: Medical Examiner

DGAP-News: G Medical Innovations Joins Forces with Serology Covid Testing to Support Safer Classroom Learning in California School Districts Amid Omicron Variant Surge

Retrieved on: 
Thursday, January 27, 2022 - 7:45pm

On average, G Medical expects to collect an average of $197.88 per patient encounter, which could amount to more than $1,000,000 in gross revenue per week.

Key Points: 
  • On average, G Medical expects to collect an average of $197.88 per patient encounter, which could amount to more than $1,000,000 in gross revenue per week.
  • This relationship is especially meaningful to us because our testing services are now endorsed by a pioneering healthcare company," said Caroline Grotewiel, CEO of Serology Covid Testing.
  • "G Medical has long been at the forefront of medical devices, offering remote patient monitoring tools to help keep patients healthy.
  • If you are interested in offering your school free on-site COVID-19 testing services, please contact Andrew Benavente at Serology Covid Testing; +1 310-747-5473; Andrew.m@Serology-Testing.com .

DGAP-News: Correction Notice to Press Release Regarding Personal Acquisitions of G Medical Shares in the Open Market

Retrieved on: 
Wednesday, January 19, 2022 - 8:24pm

Instead, Dr. Geva and Mr. McDade each intend to acquire stock in the open market following the announcement, during the next available trading window.

Key Points: 
  • Instead, Dr. Geva and Mr. McDade each intend to acquire stock in the open market following the announcement, during the next available trading window.
  • Founded in 1994, McDade Group is a growing and dynamic sales, marketing, and distribution services company headquartered in Pittsburgh, PA.
  • The company has expanded to provide solutions in distribution, category management, full-service merchandising, and consulting across the U.S. retail industry.
  • For example, G Medical is using forward-looking statements when it discusses the purchase of shares in the open market by Dr. Geva and Mr. McDade.

DGAP-News: G Medical Innovations (NASDAQ: GMVD) is forecasting incremental Q1 revenues at around $30 MM, based on revenue generated from G Medical Tests and Services' physical storefront testing locations

Retrieved on: 
Friday, January 14, 2022 - 12:05pm

G Medical Innovations (NASDAQ: GMVD) is forecasting incremental Q1 revenues at around $30 MM, based on revenue generated from G Medical Tests and Services' physical storefront testing locations

Key Points: 
  • G Medical Innovations (NASDAQ: GMVD) is forecasting incremental Q1 revenues at around $30 MM, based on revenue generated from G Medical Tests and Services' physical storefront testing locations
    The issuer is solely responsible for the content of this announcement.
  • Dr. Yacov Geva, President and CEO of G Medical Innovations, and Michael McDade, CEO of McDade Products, LLC , announced today that they acquired an undisclosed number of shares of G Medical Innovations (NASDAQ: GMVD).
  • G Medical Tests and Services currently operates storefront testing locations in California.
  • During the next few months, the company expects to expand its network of storefront testing locations in California and other U.S. regions to be announced at a later date.

DGAP-News: McDade Products, LLC and G Medical Tests Secure Additional Purchase Order for $6.5 Million, Reflecting $3.5 Million Gross Margin, to be Delivered in Q1

Retrieved on: 
Wednesday, January 12, 2022 - 12:07pm

Secure Additional Purchase Order for $6.5 Million,

Key Points: 
  • Secure Additional Purchase Order for $6.5 Million,
    Reflecting $3.5 Million Gross Margin, to be Delivered in Q1
    The issuer is solely responsible for the content of this announcement.
  • PITTSBURGH, PA - McDade Products, LLC and G Medical Tests and Services, a division of G Medical Innovations Holdings Ltd. (NASDAQ: GMVD), today announced an additional $6.5 million purchase order for two million COVID-19 PCR collection test kits.
  • G Medical will be selling these units wholesale for $3.25 each, reflecting a gross profit of approximately $3.5 million.
  • G Medical Tests and Services is delighted to provide McDade with current and future purchase orders.

DGAP-News: McDade Products, LLC Joins Forces with G Medical Tests and Services to Provide U.S. Retailers with Millions of COVID-19 at-Home PCR Test Kits

Retrieved on: 
Monday, January 10, 2022 - 12:13pm

McDade Products is a division of McDade Group, a specialty sales, marketing, and distribution company serving the U.S. retail industry.

Key Points: 
  • McDade Products is a division of McDade Group, a specialty sales, marketing, and distribution company serving the U.S. retail industry.
  • McDade Products is now accepting orders for the co-branded LiveNow PCR Collection Kit, which will retail for $9.99.
  • The diagnostic PCR (polymerase chain reaction) test detects the presence or absence of SARS-CoV2, the virus that causes COVID-19.
  • On average, tests results are expected to be available online within 24 hours from the time the sample is received.

DGAP-News: Lind to Provide $5M to Boost Prizma Sales to the Growth in Demand for Covid-19 Testing Across California

Retrieved on: 
Monday, December 20, 2021 - 11:36am

Proceeds to be used to launch 25 Covid-19 testing centers in California in Q1, 2022.

Key Points: 
  • Proceeds to be used to launch 25 Covid-19 testing centers in California in Q1, 2022.
  • The first six locations are currently in operation as of Wednesday, December 15, 2021.
  • Prizma can also be prescribed by physicians to patients with cardiac or respiratory disease, diabetes and other health issues.
  • With the explosive growth in demand for Covid testing across the country, G Medical expects its new California locations to boost Prizma sales.

Argus Research Initiates Equity Research Report Coverage on G Medical Innovations Holdings Ltd. (NASDAQ: GMVD)

Retrieved on: 
Monday, December 13, 2021 - 1:00pm

NEW YORK, Dec. 13, 2021 /PRNewswire/ --Argus Research, an independent investment research firm, has launched Equity Research Report coverage on G Medical Innovations Holdings Ltd. (NASDAQ: GMVD)

Key Points: 
  • NEW YORK, Dec. 13, 2021 /PRNewswire/ --Argus Research, an independent investment research firm, has launched Equity Research Report coverage on G Medical Innovations Holdings Ltd. (NASDAQ: GMVD)
    Click Here to view full Argus Equity Research Report.
  • Founded in 2014, Israel-based G Medical Innovations Holdings Inc. develops and manufactures mobile health products.
  • G Medical is also preparing to file an application for Prizma with the Chinese National Medical Products Administration (NMPA).
  • About G Medical Innovations Holdings Ltd. (NASDAQ: GMVD) gmedinnovations.com
    Founded in 2014, Israel-based G Medical Innovations Holdings Inc. develops and manufactures mobile health products and provides telemedicine services.

DGAP-News: G Medical Innovations Holdings Ltd. Scheduled to Launch Covid-19 Testing Centers in California as Part of New Direct-to-Consumer Initiative

Retrieved on: 
Wednesday, December 1, 2021 - 1:14pm

Scheduled to Launch Covid-19 Testing Centers in California as Part of New Direct-to-Consumer Initiative

Key Points: 
  • Scheduled to Launch Covid-19 Testing Centers in California as Part of New Direct-to-Consumer Initiative
    The issuer is solely responsible for the content of this announcement.
  • G Medical Innovations Holdings Ltd. (NASDAQ:GMVD) (the "Company"), a telehealth, medical device, and remote patient monitoring company providing clinical-grade solutions for consumers, medical professionals, and healthcare institutions, today announced plans to open as many as 25 Covid-19 testing centers in California in Q1, 2022.
  • With the explosive growth in demand for Covid testing across the country, G Medical expects its new California locations to boost Prizma sales.
  • About G Medical Innovations Holdings Ltd.
    G Medical Innovations Holdings Ltd. Is an early commercial stage healthcare company engaged in the development of next generation mHealth and telemedicine solutions and monitoring service platforms.

G Medical Innovations Holdings Ltd. to Participate at the Benzinga Healthcare Small Cap Conference

Retrieved on: 
Monday, September 27, 2021 - 1:30pm

The Benzinga Healthcare Small Cap Conference will be taking place from September 29-30, 2021.

Key Points: 
  • The Benzinga Healthcare Small Cap Conference will be taking place from September 29-30, 2021.
  • Investors interested in joining the G Medical presentation can register for a free spectator pass at the link below:
    About G Medical Innovations Holdings Ltd.
    G Medical Innovations Holdings Ltd. is an early commercial stage healthcare company engaged in the development of next generation mHealth and telehealth solutions and monitoring service platforms.
  • The Benzinga Healthcare Small Cap Conference bridges the gap between Small Cap companies, investors, and traders.
  • For example, G Medical is using forward-looking statements when it discusses presenting at the online Benzinga Healthcare Small Cap Conference.